New biosafety level 2 laboratories to support enzyme development
Biotech firms VALANX Biotech and Fina Biosolutions have announced a collaborative agreement to commercialise ClickCRM, an engineered version of the carrier protein CRM197 designed to accelerate conjugate vaccine development. The partnership, announced on 29 October 2024, combines VALANX’s expertise in site-specific protein conjugation with FinaBio’s established presence in conjugate vaccine development.
At this year’s Human Proteome Organization (HUPO) World Congress in Dresden, proteomics specialist Biognosys unveiled significant developments in protein analysis technology, with particular emphasis on their novel P2 Plasma Enrichment System.
Takara Bio Europe has expanded its Gothenburg facility with a new custom manufacturing laboratory, significantly boosting its capacity to produce molecular biology reagents for the EMEA region. The facility, which became operational on 1 October 2024, is capable of manufacturing up to 600,000 reactions weekly, addressing the growing demands of academic research institutions, diagnostic laboratories, […]
Partnership focuses on Cue system integration
SGS, the global testing and certification organisation, has unveiled a specialised consultancy service focused on transforming the complex process of clinical trial data submissions. The CDISC Open Rules Consultancy aims to address the increasingly intricate requirements of regulatory compliance in clinical research.
The laboratory informatics company Sapio Sciences has announced a significant expansion of its partnership with Amazon Web Services (AWS), marking a potential watershed moment in the application of artificial intelligence to drug discovery and development workflows.
A novel integration of protein footprinting and ion mobility mass spectrometry technologies promises to accelerate structural biology research in the biopharmaceutical sector, following a collaboration announced by GenNext Technologies and Agilent.
The Cardiff-based antibody design company Antiverse has secured £3.5 million in additional seed funding, bringing their total equity financing to £7.2 million. The investment round, spearheaded by i&i Biotech Fund I and Kadmos Capital, saw participation from existing investors including InnoSpark Ventures, UKI2S, Tensor Ventures, and AngelHub.
A recent report published by the Food Standards Agency in the UK [Patterns and prevalence of adult food allergy (PAFA); https://shorturl.at/jnaLY] estimates that around 6% of the UK adult population have a clinically confirmed IgE-mediated food allergy.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
